Integer (ITGR) Projected to Post Quarterly Earnings on Thursday

Integer (NYSE:ITGR) will likely be posting its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Integer to post earnings of $1.70 per share and revenue of $462.7250 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 19, 2026 at 9:00 AM ET.

Integer Stock Up 0.7%

Shares of ITGR stock opened at $85.92 on Tuesday. The firm’s fifty day moving average price is $81.75 and its two-hundred day moving average price is $88.59. The company has a current ratio of 3.71, a quick ratio of 2.45 and a debt-to-equity ratio of 0.70. Integer has a 1 year low of $62.00 and a 1 year high of $144.76. The firm has a market capitalization of $3.01 billion, a P/E ratio of 35.95, a PEG ratio of 0.79 and a beta of 0.77.

Integer declared that its Board of Directors has authorized a stock buyback plan on Tuesday, November 4th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 8.3% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

ITGR has been the topic of several analyst reports. Piper Sandler dropped their target price on Integer from $155.00 to $82.00 and set an “overweight” rating on the stock in a report on Friday, October 24th. Benchmark reaffirmed a “hold” rating on shares of Integer in a research report on Friday, October 24th. Citigroup upped their price objective on Integer from $69.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Truist Financial increased their price objective on Integer from $86.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Finally, Raymond James Financial restated an “outperform” rating and set a $95.00 target price (down from $143.00) on shares of Integer in a report on Friday, October 24th. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Integer has a consensus rating of “Hold” and a consensus price target of $98.38.

Institutional Investors Weigh In On Integer

Several hedge funds have recently added to or reduced their stakes in ITGR. Kestra Advisory Services LLC boosted its holdings in Integer by 0.6% during the fourth quarter. Kestra Advisory Services LLC now owns 21,424 shares of the medical equipment provider’s stock worth $1,680,000 after purchasing an additional 136 shares during the last quarter. Orion Porfolio Solutions LLC lifted its position in shares of Integer by 1.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 9,755 shares of the medical equipment provider’s stock worth $1,200,000 after buying an additional 138 shares in the last quarter. Lido Advisors LLC lifted its position in shares of Integer by 5.5% during the 4th quarter. Lido Advisors LLC now owns 2,887 shares of the medical equipment provider’s stock worth $226,000 after buying an additional 151 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Integer by 8.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,543 shares of the medical equipment provider’s stock worth $312,000 after buying an additional 188 shares during the last quarter. Finally, MML Investors Services LLC grew its holdings in shares of Integer by 2.4% in the second quarter. MML Investors Services LLC now owns 8,222 shares of the medical equipment provider’s stock valued at $1,011,000 after acquiring an additional 196 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.